Bruised Roche Wins Another UK Perjeta Round With Price Cut
Executive Summary
In the latest round of what appears to have been a bruising set of price negotiations for Roche, the UK’s cost effectiveness agency NICE has recommended Perjeta in another breast cancer setting.